EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Effect of the MyDéfi Smartphone Application on Binge Drinking Among University Students: Protocol of a Double‐Blind Multicenter Prospective National Randomized Controlled Trial Using Phosphatidylethanol as a Biomarker—The SMARTBINGE Trial

Camille André iD, Pierre Sauton iD, Méléna Dreinaza iD, Momar Diouf iD, Sandra Bodeau iD, Margaret Martinetti iD, Raphaël Trouillet iD, Clara de Groote iD, Jean-Louis Nandrino iD, Adèle Alexandre, Farid Benzerouk iD, Fabien Gierski iD und 4 weitere

International Journal of Methods in Psychiatric Research · 2025

DOI: 10.1002/mpr.70014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Methods in Psychiatric Research, 2025. Verfasst von Camille André und 15 weiteren Autor:innen. Beteiligte Einrichtung: Groupe de Recherche sur l'Alcool & les Pharmacodépendances, INSERM UMR 1247, Université de Picardie Jules Verne, Amiens, France. Hauptthemen laut MEDLINE: Binge Drinking, Glycerophospholipids, Students, Mobile Applications. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National Du Cancer, Institut pour la Recherche en Santé Publique.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The purpose of this paper is to describe a study protocol of a clinical trial exploring the effectiveness of the new mobile application MyDéfi proposing personalized feedback, on both alcohol consumption and quality of life, as well as the blood alcohol exposure biomarker phosphatidylethanol, in university students displaying binge drinking behavior.

Methods

This prospective national multicentric randomized, two‐arm (1:1), double‐blind controlled trial will recruit 628 students (aged 18–25 years) with binge drinking behavior. Participants will be randomized in the “intervention” group (personalized feedback) or the “control” group (generic feedback) and will undergo four monthly visits. Monthly dried blood spot sample for measuring phosphatidylethanol concentration and online questionnaires will be collected. Our primary objective is to assess the reduction weekly standard drinks, through self‐report gathered via MyDéfi. Secondary objectives will evaluate the application's impact on the dosage of phosphatidylethanol blood concentration and on quality of life”.

Results

Recruitment started in March 2024 and will end in March 2026.

Conclusion

This study aims to determine the effectiveness of two versions of the same mobile application (generic vs. personalized feedback) on alcohol consumption in students displaying binge drinking behavior. The effectiveness of the application will be measured, with a secondary objective of quantifying phosphatidylethanol. Our study will open new perspectives on the use of digital interventions for students who do not actively seek treatment. Trial Registration Trial registration number (NCT06084832), the date of registration (10th October 2023) and when this was done (16th October 2023). https://clinicaltrials.gov/study/NCT06084832

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Binge DrinkingGlycerophospholipidsStudentsMobile ApplicationsHumansDouble-Blind MethodYoung AdultAdolescentAdultMaleFemaleUniversitiesBiomarkersSmartphoneRandomized Controlled Trials as TopicProspective StudiesMulticenter Studies as TopicQuality of Life

Stichwörter der Autor:innen

binge drinkingdigital interventione‐healthmobile applicationphosphatidylethanol

Substanzen

phosphatidylethanolGlycerophospholipidsBiomarkers

Autor:innen und Institutionen

  • Groupe de Recherche sur l'Alcool & les Pharmacodépendances, INSERM UMR 1247, Université de Picardie Jules Verne, Amiens, France.
  • Department of Statistics, Amiens Hospital University, Amiens, France.
  • Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, France.
  • University of Paul Valéry Montpellier 3, Montpellier, France.
  • Laboratory SCALab, UMR CNRS 9193, University of Lille, Villeneuve d'Ascq, France.
  • Cognition Health Society Laboratory (C2S - EA 6291), University of Reims Champagne Ardenne, Reims, France.

ORCID-Profile: Camille André, Pierre Sauton, Méléna Dreinaza, Momar Diouf, Sandra Bodeau, Margaret Martinetti, Raphaël Trouillet, Clara de Groote, Jean-Louis Nandrino, Farid Benzerouk, Fabien Gierski, Pascal Perney, Laure Grellet, Judith André, Mickael Naassila

Förderung

  • Institut National Du Cancer
  • Institut pour la Recherche en Santé Publique

Zitieren

APA

André, C., Sauton, P., Dreinaza, M., Diouf, M., Bodeau, S., Martinetti, M., Trouillet, R., de Groote, C., Nandrino, J. L., Alexandre, A., Benzerouk, F., Gierski, F., Perney, P., Grellet, L., André, J., & Naassila, M. (2025). Effect of the MyDéfi Smartphone Application on Binge Drinking Among University Students: Protocol of a Double‐Blind Multicenter Prospective National Randomized Controlled Trial Using Phosphatidylethanol as a Biomarker—The SMARTBINGE Trial. International Journal of Methods in Psychiatric Research. https://doi.org/10.1002/mpr.70014

Vancouver

André C, Sauton P, Dreinaza M, Diouf M, Bodeau S, Martinetti M, et al. Effect of the MyDéfi Smartphone Application on Binge Drinking Among University Students: Protocol of a Double‐Blind Multicenter Prospective National Randomized Controlled Trial Using Phosphatidylethanol as a Biomarker—The SMARTBINGE Trial. International Journal of Methods in Psychiatric Research. 2025. doi:10.1002/mpr.70014

BibTeX
@article{Andr2025,
  author = {André, Camille and Sauton, Pierre and Dreinaza, Méléna and Diouf, Momar and Bodeau, Sandra and Martinetti, Margaret and Trouillet, Raphaël and de Groote, Clara and Nandrino, Jean-Louis and Alexandre, Adèle and Benzerouk, Farid and Gierski, Fabien and Perney, Pascal and Grellet, Laure and André, Judith and Naassila, Mickael},
  title = {Effect of the MyDéfi Smartphone Application on Binge Drinking Among University Students: Protocol of a Double‐Blind Multicenter Prospective National Randomized Controlled Trial Using Phosphatidylethanol as a Biomarker—The SMARTBINGE Trial},
  journal = {International Journal of Methods in Psychiatric Research},
  year = {2025},
  doi = {10.1002/mpr.70014}
}
Kostenlos starten →